abstract |
The present invention relates to hydroxyl steroid dehydrogenase inhibitors 11-? type 1, mineralocorticoid (MR) receptor antagonists, and pharmaceutical compositions thereof. The compounds of the invention may be useful in the treatment of various diseases associated with the expression or activity of hydroxyl steroid dehydrogenase 11-? Type 1 and / or diseases associated with excess aldosterone. |